Form 4: Enanta Pharmaceuticals Chief Business Officer Acquires 75,000 Stock Options

Enanta Pharmaceuticals' Chief Business Officer, Brendan Luu, was granted 75,000 stock options on November 27, 2024.

Summary

• Brendan Luu, the Chief Business Officer of Enanta Pharmaceuticals, was granted 75,000 stock options on November 27, 2024.
• The options have an exercise price of $8.83 per share.
• The options will vest quarterly over four years from the grant date, meaning they will become exercisable in stages.
• The options expire on November 27, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to slightly positive as it aligns executive interests with shareholders.

Positives

• The grant of stock options to a key executive aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of compensation for executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry for executive compensation.
• The vesting schedule of four years is also typical for such grants, encouraging long-term commitment.
• The exercise price of $8.83 is specific to Enanta's stock price at the time of the grant.

Stakeholder Impact

• The stock option grant could positively impact shareholder value if the executive's performance leads to company growth.
• The vesting schedule encourages the executive's long-term commitment to the company.

Key Dates

Keywords

stock options, executive compensation, insider trading, Enanta Pharmaceuticals, Brendan Luu, vesting, biotechnology